High-flow nasal cannula therapy in patients with COVID-19 in intensive care units in a country with limited resources: a single-center experience.

Objective: This study was performed to determine the outcomes of patients with coronavirus disease 2019 (COVID-19) who developed hypoxemic respiratory failure necessitating high-flow nasal cannula (HFNC) therapy and to identify the predictors of HFNC therapy success.

Methods: This retrospective observational study involved all patients treated with HFNC therapy at a center for COVID-19 in Viet Nam from August to October 2021.

Results: The study recruited 302 patients.